EFFECTOR Therapeutics Correlations
| EFTRWDelisted Stock | USD 0 0.00 0.00% |
The current 90-days correlation between EFFECTOR Therapeutics and Effector Therapeutics is 0.16 (i.e., Average diversification). The correlation of EFFECTOR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
EFFECTOR Therapeutics Correlation With Market
Significant diversification
The correlation between EFFECTOR Therapeutics and DJI is 0.07 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding EFFECTOR Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
EFFECTOR |
The ability to find closely correlated positions to EFFECTOR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EFFECTOR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EFFECTOR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling EFFECTOR Therapeutics to buy it.
Moving together with EFFECTOR Pink Sheet
| 0.66 | PPERF | Bank Mandiri Persero | PairCorr |
| 0.67 | BKRKF | PT Bank Rakyat | PairCorr |
| 0.68 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against EFFECTOR Pink Sheet
| 0.9 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.88 | HD | Home Depot | PairCorr |
| 0.87 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.83 | PTAIF | PT Astra International | PairCorr |
| 0.82 | INTC | Intel Fiscal Year End 23rd of January 2025 | PairCorr |
| 0.81 | CSCO | Cisco Systems Aggressive Push | PairCorr |
| 0.79 | SSNLF | Samsung Electronics | PairCorr |
| 0.78 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.72 | T | ATT Inc Sell-off Trend | PairCorr |
| 0.7 | WMT | Walmart Aggressive Push | PairCorr |
| 0.69 | XOM | Exxon Mobil Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.63 | GE | GE Aerospace Fiscal Year End 28th of January 2025 | PairCorr |
| 0.62 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.59 | BAC | Bank of America Aggressive Push | PairCorr |
| 0.55 | DD | Dupont De Nemours Fiscal Year End 4th of February 2025 | PairCorr |
| 0.49 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
Related Correlations Analysis
| -0.06 | 0.4 | 0.04 | -0.28 | EFTR | ||
| -0.06 | 0.06 | 0.03 | 0.23 | CELUW | ||
| 0.4 | 0.06 | -0.15 | -0.5 | HUMAW | ||
| 0.04 | 0.03 | -0.15 | 0.03 | NRXPW | ||
| -0.28 | 0.23 | -0.5 | 0.03 | RVPHW | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between EFFECTOR Pink Sheet performing well and EFFECTOR Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze EFFECTOR Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| EFTR | 7.57 | (4.61) | 0.00 | (14.08) | 0.00 | 8.70 | 88.91 | |||
| CELUW | 13.85 | 3.14 | 0.10 | (0.22) | 14.31 | 46.53 | 110.24 | |||
| HUMAW | 5.12 | (0.37) | 0.00 | (0.42) | 0.00 | 12.82 | 44.32 | |||
| NRXPW | 10.28 | 0.44 | 0.01 | (0.42) | 15.05 | 26.00 | 62.80 | |||
| RVPHW | 13.81 | 2.77 | 0.14 | (34.26) | 15.02 | 28.57 | 129.53 |
EFFECTOR Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with EFFECTOR Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of EFFECTOR Therapeutics could also be used in its relative valuation, which is a method of valuing EFFECTOR Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
EFFECTOR Therapeutics Corporate Management
| Siegfried Reich | CoFounder Advisor | Profile | |
| Mayank MD | Chief Officer | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Alana MBA | Chief Officer | Profile | |
| Premal MD | Chief Officer | Profile | |
| Davide Ruggero | CoFounder Board | Profile | |
| Douglas MD | Chief Officer | Profile |
Still Interested in EFFECTOR Therapeutics?
Investing in delisted pink sheets can be risky, as the pink sheet is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.